Fosmanogepix Continues to Show Potential Against Invasive Mold Disease

In a phase 2 trial, this novel antifungal agent yielded better outcomes than historically seen with amphotericin B.

Therapeutic options for patients with invasive mold disease (IMD) include mold-active triazoles, echinocandins, and amphotericin B — however, these drugs have all been limited by toxicity and lack of effectiveness. The novel agent fosmanogepix, by inhibiting glycosylphosphatidylinositol synthesis, blocks fungal adhesion to (and invasion of) host cells. In a noncomparative, manufacturer-supported and conducted phase 2 study, 21 adults with limited therapeutic options and IMD caused by Aspergillus species and rare molds received fosmanogepix for up to 42 days at 8 centers in 4 countries.

Mortality at 42 days was 25%, lower than the 45% estimate predefined historically based on treatment with amphotericin B. Three participants discontinued trea…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Fosmanogepix Continues to Show Potential Against Invasive Mold Disease

Topics

Reviewing Author